Allergan's $750M Deal Among Pharma's Top Antitrust Payouts
A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly...To view the full article, register now.
Already a subscriber? Click here to view full article